On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

The boss of US pharmaceutical giant Eli Lilly has told the BBC there is no looking back from Donald Trump's decision to ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Shares in Swiss drugmaker Novartis (NVS) were looking perkier today as it set out plans to invest $23 billion in U.S. manufacturing to beat the ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.

Eli Lilly has recently announced several developments ... Their $23 billion investment in expanding manufacturing capacity since 2020 also positioned the company well for future product demands.